AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02790840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg oral capsules administered twice daily for 10 days
Study NCT02790840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
Study NCT02790840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
Study NCT00532129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
Study NCT00532129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: 10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
Study NCT04725045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific: Study tool computer
Description: compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
Study NCT04725045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific: Study tool computer
Description: compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
Study NCT03005730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
Study NCT03005730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy placebo
Description: The placebo portable. The aperture size of device is 4 cm2 .
Study NCT00429143 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI twice daily days 6-9 prior to transplant (HSCT)
Study NCT00429143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: DLI given 6 days prior to transplant (HSCT).
Study NCT00429143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
Study NCT00429143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus given one day prior to transplant (HSCT).
Study NCT00429143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF given one day prior to transplant (HSCT).
Study NCT00429143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant (HSCT)
Description: CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
Study NCT02824393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cell
Description: Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
Study NCT01741493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Oral administration of ABT-494 capsules
Study NCT01741493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo capsules
Study NCT01741493 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tofacitinib
Description: Oral administration
Study NCT02948764 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vacuum-Assisted Biopsy
Description: The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
Study NCT02681367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze all policy
Description: Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
Study NCT03134859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tummy Time
Description: deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
Study NCT01504295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metadoxine
Description: Improve Liver Function and Reduce ALcohol Use
Study NCT01504295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metadoxine
Description: Improve Liver Function and Reduce ALcohol Use
Study NCT00666081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK690693
Description: Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
Study NCT04495946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sepsis Transition and Recovery (STAR) program
Description: In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
Study NCT04495946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
Study NCT02714491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erigo + Music
Description: The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation.
Study NCT02714491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erigo + Metronome
Description: The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation.
Study NCT02714491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erigo + Silence
Description: The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation.
Study NCT01354613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
Study NCT00357149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy
Study NCT01466491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block technique with lidocaine
Description: The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
Study NCT01466491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracervical block technique with lidocaine
Description: The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
Study NCT03069040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve sparing radical hysterectomy
Description: Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
Study NCT03069040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy
Description: In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
Study NCT03218280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Study NCT03844087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplanar neuromuscular training
Description: See arm description
Study NCT02871817 — intervention group
Intervention type: OTHER
Intervention: Paxos Checkup Study Mobile Medical Application
Description: The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
Study NCT00357149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant cisplatin, 5-FU and radiotherapy
Study NCT04244240 — intervention group
Intervention type: BEHAVIORAL
Intervention: BEARNI Tool
Description: BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available.
Study NCT01340222 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological samples
Description: 4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
Study NCT04195490 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: feminizing genitoplasty
Description: feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
Study NCT00876863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERE-110: Adeno-Associated Virus injection Surgery
Description: Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.
Study NCT00876863 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Surgery
Description: Placebo Surgery
Study NCT06239883 — intervention group
Intervention type: OTHER
Intervention: Voiding diary
Description: The patients with diagnosed OSA will be asked to fill in the voiding diary.
Study NCT01747915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 1
Description: Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
Study NCT01747915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 2
Description: Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
Study NCT01747915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
Study NCT00094926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal Consta
Description: 25, 37.5 or 50mg IM injections every 2wks for 52wks
Study NCT00094926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo IM injections every 2wks for 52wks
Study NCT00737724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simultaneous ARV and antiMTB
Description: Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
Study NCT00737724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred RV and antiMTB treatment
Description: Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
Study NCT03907787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zingiber officinale and Acmella oleracea
Description: Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
Study NCT00454272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Study NCT00454272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT04085146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized optimal positive end-expiratory pressure
Description: Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
Study NCT04085146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional positive end-expiratory pressure
Description: A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
Study NCT01470131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib 6 mg/kg/day
Study NCT01470131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01605773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: Dose individually adjusted and conducted according to labeling
Study NCT03247517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg SPN-812
Description: 200mg SPN-812 was administered once daily and compared to placebo
Study NCT03247517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg SPN-812
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study NCT02196701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered by subcutaneous injection every other week.
Study NCT02196701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate was provided as 2.5 mg tablets for oral administration.
Study NCT01099527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: dose escalation of capecitabine, everolimus
Study NCT01099527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: dose escalation of capecitabine, everolimus
Study NCT00894738 — intervention group
Intervention type: PROCEDURE
Intervention: Testing (MRS, US, DEXA, blood tests)
Description: Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
Study NCT01470131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Standard therapy (cycles of bortezomib)
Study NCT01470131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Standard therapy (cycles of bortezomib)
Study NCT01470131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard therapy (cycles of dexamethasone)
Study NCT01470131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Standard therapy (cycles of dexamethasone)
Study NCT03909412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
Study NCT01605773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: Dose individually adjusted and conducted according to labeling
Study NCT01316731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single legged exercise
Description: A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
Study NCT04911829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Study NCT04911829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Study NCT04587596 — intervention group
Intervention type: OTHER
Intervention: Pain education
Description: 70 minute lecture about chronic pain and one focus group afterwards
Study NCT03067194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 100 MG
Description: Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
Study NCT03067194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
Study NCT00003828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study NCT01154595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Doz(r) - Ready-to-Use Food
Description: 47g Plumpy Doz(r) per day per child
Study NCT01154595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food-for-Training
Description: Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
Study NCT01154595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food-for-Training
Description: Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
Study NCT01167153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine
Description: Valsartan/Amlodipine 80/5mg single pill combination (SPC)
Study NCT01167153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
Study NCT03194620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thearubigins
Description: Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
Study NCT03194620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theaflavins
Description: Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
Study NCT03194620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procyanidin Dimer B2 (DB2)
Description: Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.